Publications by authors named "P Manzoni"
At the beginning of the pandemic, SARS-CoV-2 infection represented a great medical burden worldwide, as targeted and effective therapeutic options were lacking. This resulted in the revival of existing molecules and the increasing popularity of over-the-counter nutritional supplements. Among the latter, lactoferrin has been investigated as an adjuvant in COVID-19 therapy with conflicting results, mainly depending on different study designs.
View Article and Find Full Text PDFArticle Synopsis
- Respiratory syncytial virus (RSV) infections are increasingly linked to neurological issues like encephalitis and encephalopathy, prompting a systematic review and meta-analysis of relevant studies and case reports.
- The analysis included 15 studies with over 7,700 RSV infections and found a pooled prevalence of 2.20 cases of encephalitis/encephalopathy per 100 RSV cases, suggesting a significant association.
- While RSV detection in the central nervous system (CNS) was rare (about 17.86% of cases), it was more common in males and often resulted in long-term complications, highlighting the virus as a notable but infrequent cause of encephalitis.
Article Synopsis
- - A systematic review and meta-analysis evaluated the effectiveness of nirsevimab, a monoclonal antibody, in preventing lower respiratory tract diseases caused by RSV in infants, analyzing data from 5 randomized controlled trials (RCTs) and 7 real-world studies.
- - The analysis, covering 45,238 infants, found an overall immunization efficacy of 88.40% in reducing hospital admissions due to RSV, although efficacy decreased with longer observation times.
- - While nirsevimab proved effective, the increased risk of breakthrough infections over longer follow-up periods suggests the need for future research to refine public health strategies during RSV seasons.
A systematic review and meta-analysis was designed in order to ascertain the effectiveness of respiratory syncytial virus (RSV) vaccination in preventing lower respiratory tract diseases (LRTD) in older adults (age ≥ 60 years). Studies reporting on randomized controlled trials (RCTs) were searched for in three databases (PubMed, Embase, and Scopus) and the preprint repository medRxiv until 31 March 2024. A total of nine studies were eventually included, two of which were conference proceedings.
View Article and Find Full Text PDFBackground: Visceral fat produces angiogenic factors such as vascular endothelial growth factor that promote tumoral growth. However, its influence on outcome for patients with advanced cancer treated with anti-angiogenic agents is controversial.
Aims: The aim of this study was to determine whether visceral fat volume, visceral fat area and body mass index are associated with outcome in patients receiving first-line bevacizumab-based treatment for metastatic colorectal cancer.